Current Report Filing (8-k)
22 April 2023 - 6:06AM
Edgar (US Regulatory)
0001557376
false
0001557376
2023-04-17
2023-04-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): April 17, 2023
ORGANICELL REGENERATIVE MEDICINE, INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-55008 |
|
47-4180540 |
(State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
3321 College Avenue, Suite 246, Davie FL |
|
33314 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (888) 963-7881
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
None |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As
used in this Current Report on Form 8-K (this “Report”), unless otherwise indicated, the terms “the
Company,” “Organicell,” “we,” “us” and “our” refer
to Organicell Regenerative Medicine, Inc. and its subsidiaries.
Item
4.01 Changes in Registrant’s Certifying Accountant
(a) Release of Previous Independent Registered Public Accounting Firm
(i)
On April 17, 2023, the Company released Marcum LLP (“Marcum”) as the Company’s independent registered
public accounting firm. The decision to release Marcum as the Company’s independent registered public accounting firm was
approved by the Audit Committee of our Board of Directors on April 17, 2023.
(ii)
Marcum’s reports on the Company’s financial statements for the fiscal years ended October 31, 2022 and October 31, 2021
did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or
accounting principles, except for except that such reports contained an explanatory paragraph in respect to uncertainty as to the
Registrant’s ability to continue as a going concern.
(iii)
During the Company’s two most recent fiscal years ended October 31, 2022 and October 31, 2021 and the subsequent interim
period through the date of this Report, there were no disagreements, within the meaning of Item 304(a)(1)(iv) of Regulation S-K
promulgated under the Securities Exchange Act of 1934, as amended (“Regulation S-K”), and the related
instructions thereto, with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused it to make reference to
the subject matter of the disagreements in connection with its reports. Also, during this same period, there were no reportable
events within the meaning of Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto.
(iv)
The Company provided Marcum with the disclosures under this Item 4.01(a) and requested Marcum to furnish the Company with a
letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made by the Company in this Item
4.01(a) and, if not, stating the respects in which it does not agree. Marcum’s letter is filed as Exhibit 16.1 to
Report.
(b) Appointment of New Independent Registered Public Accounting Firm
(i)
On April 17 2023, the Audit Committee of our Board of Directors approved the appointment of Weinberg & Company P.A.
(“Weinberg”) as the Company’s new independent registered public accounting firm.
(ii)
During the Company’s two most recent fiscal years ended October 31, 2022 and October 31, 2021, and the subsequent interim
period through the date of this Report, neither the Company nor anyone acting on its behalf consulted with Weinberg regarding any of
the matters described in Items 304(a)(2)(i) and (ii) of Regulation S-K.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
April 21, 2023 |
ORGANICELL
REGENERATIVE MEDICINE, INC. |
|
|
|
By: |
/s/
Ian Bothwell |
|
|
Ian
Bothwell
Interim Chief Executive Officer and
Chief
Financial Officer |
Organicell Regenerative ... (QB) (USOTC:OCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Organicell Regenerative ... (QB) (USOTC:OCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024